Navigation Links
Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases
Date:5/6/2009

S. aureus; S. Lemaire, K. Kosowska-Shick, P. Appelbaum, F. Van Bambeke, P. Tulkens
  • P 1090: The safety of single ascending oral doses of TR-701, a novel oxazolidinone prodrug antibiotic; P. Bien, P. Prokocimer, KA. Munoz, J. Bohn
  • P 1089: The safety of multiple ascending oral doses of TR-701, a novel oxazolidinone prodrug antibiotic; P. Bien, P. Prokocimer, KA. Munoz, J. Bohn
  • P 1103: Characterization of resistance following serial passage of Staphylococcus aureus in the presence of the novel oxazolidinone TR-700 and linezolid; J. Locke, K. Shaw
  • P 1104: Characterization of the novel oxazolidinone TR-700 and linezolid spontaneous mutation frequencies and resistance mechanisms in Staphylococcus aureus; J. Locke, K. Shaw

    • Copies of these posters will be available on the Trius Web site following the ECCMID meeting: http://www.triusrx.com/posters.php.

    About Trius Therapeutics

    Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by drug-resistant pathogens. The company's lead drug candidate, torezolid, is a second generation oral and IV oxazolidinone antibiotic with potent activity against drug-resistant Gram-positive bacterial pathogens including those resistant to Zyvox(R), the only marketed antibacterial drug of the oxazolidinone class. Trius has recently completed Phase 2 testing of torezolid in a U.S. based multi-center trial. Trius' pipeline includes two preclinical programs with lead candidates being developed to treat serious infections caused by Gram-negative bacterial pathogens. For more information, visit www.triusrx.co
    '/>"/>

    SOURCE Trius Therapeutics, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3

    Related medicine technology :

    1. Trius Completes Enrollment in Phase 2 Clinical Trial Evaluating Torezolid (TR-701) in Patients With Complicated Skin and Skin Structure Infections
    2. Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
    3. Trius Doses First Patient in Antibacterial Phase 2 Trial
    4. PacificGMP Completes GMP Product Fill for Trius Therapeutics
    5. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
    6. Hyperion Therapeutics Receives Orphan Drug Designation for HPN-100 for the Treatment of Urea Cycle Disorders
    7. Sirion Therapeutics Announces Clinical Data Presentations at the 2009 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
    8. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
    9. Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders
    10. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
    11. Vantia Therapeutics Pipeline Continues to Mature
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/17/2013)... 17, 2013  Sanofi (EURONEXT: SAN and NYSE: ... JAKARTA , examining the selective JAK2 inhibitor ... both dose groups. The primary endpoint assessed the proportion ... with data reported in previous trials, the most common ... results will be presented at an upcoming medical congress. ...
    (Date:5/17/2013)... -- Sinovac Biotech Ltd. (Nasdaq: SVA ), a ... today announced that it will release its unaudited financial results ... on Tuesday, May 28, 2013.  The Company will host a ... EDT (May 28, 2013 at 8:00 p.m. China Standard Time) ... on recent corporate developments. To access the conference ...
    (Date:5/16/2013)... and ZURICH , May 17, 2013 /PRNewswire/ ... Science, Technology and Research (A*STAR) and Switzerland,s ... volunteer has been dosed in a Phase 1 clinical trial ... bacteriophage Qbeta virus-like particle (VLP) technology. In this first Phase ... vaccine candidate and its potential to protect against H1N1 influenza ...
    Breaking Medicine Technology:Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 2Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6
    (Date:5/19/2013)... ATS 2013, PHILADELPHIA ─ Gourmands and foodies everywhere have ... a little peppery zing to both sweet and savory ... shows purified components of the spicy root also may ... , The results of the study will be presented ... characterized by bronchoconstriction, a tightening of the bronchial tubes ...
    (Date:5/19/2013)... In partnership with the medical practice online marketing company, ... an SEO website for dentists. The purpose of the site ... http://www.e-dentists.com/ , A perk to the service is ... see results. Dentists can request the keywords they want included ... Media Surge, LLC rank high for competitive keywords. Dentists can ...
    (Date:5/19/2013)... 19, 2013 According to a ... and Forecast (2013 – 2018): By Applications (Healthcare ... Technology (CCD, CMOS, Contact IS, Infrared, X-Ray) And ... sensor market was $8.00 billion in 2012 and ... at an estimated CAGR of 3.84% from 2013 ...
    (Date:5/19/2013)... York (PRWEB) May 19, 2013 The ... Case Management Conference was recently convened for hundreds of ... multidistrict litigation now underway in U.S. District Court, Southern ... the Court’s website on May 14th, the Conference addressed ... was also reported during the Conference that Defendants submitted ...
    (Date:5/19/2013)... Vegas Hotel Escapes, the premier ... the launch it's all new vacation packages for the ... 5/19/2013. Consumers traveling to Las Vegas will be pleased ... VegasHotelEscapes.com's website. Travelers will be pleased to know that ... , Vegas Hotel Escapes specializes in helping consumers ...
    Breaking Medicine News(10 mins):Health News:Ginger compounds may be effective in treating asthma symptoms 2Health News:Effective New Dental SEO Solution Launched by E-dentists.com in Partnership with JD Media Surge, LLC 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 3Health News:Pradaxa Lawyers at Bernstein Liebhard LLP Report on Recent Status Conference in Federal Pradaxa Litigation 2Health News:Pradaxa Lawyers at Bernstein Liebhard LLP Report on Recent Status Conference in Federal Pradaxa Litigation 3
    ... health centers have become the centerpiece of the nation,s efforts ... experience a greater need for primary care providers, who already ... Center (BMC) and Boston University School of Medicine (BUSM) medical ... center mission to address this need. This call to action ...
    ... Supporting a worthy cause can make great wine taste even ... partnership with Beringer Vineyards and the Pennsylvania Breast Cancer Coalition, ... of donation during Breast Cancer Awareness Month. , During ... Beringer White Zinfandel and White Merlot sold in PA Wine ...
    ... Committee handed a major victory to the health care industry ... a "public option" to compete against private health insurance providers ... system. The industry has fought the public option with lobbying ... fearing that the proposed policy would cut into their record ...
    ... Noted Healthcare Entrepreneur Alan B. Miller is a Fitting ... his Ideas , WILLIAMSBURG, Va., Sept. 30 The ... host the grand opening and public dedication of its exceptional ... 2009. , (Logo: http://www.newscom.com/cgi-bin/prnh/20051111/DCF019LOGO-b ) , ...
    ... October 5, 2009, 12 Noon Central Time , ... Hospital Patient Safety Organization and Mark J. Neuberger, Foley & ... is almost upon us and companies across the globe are ... influenza pandemic plan as we await the arrival of the ...
    ... Sept. 30 Select Medical Holdings Corporation ("Select") (NYSE: ... that it successfully completed its initial public offering of common ... sold 30,000,000 shares in the offering. Select,s stock began ... 2009 under the Symbol "SEM." , Total net proceeds to ...
    Cached Medicine News:Health News:A need for leadership in primary care 2Health News:PLCB, PA Breast Cancer Coalition, Beringer Wine Partner To Support Breast Cancer Awareness 2Health News:Insurance Industry Successful in Initial Fight Against Public Option; Public Feels Left Out 2Health News:Insurance Industry Successful in Initial Fight Against Public Option; Public Feels Left Out 3Health News:Revolutionary B-School Building, Named for Healthcare Entrepreneur Alan B. Miller, To Be Dedicated 2Health News:Revolutionary B-School Building, Named for Healthcare Entrepreneur Alan B. Miller, To Be Dedicated 3Health News:Society of Corporate Compliance and Ethics to host What Compliance Professionals Need to Know about H1N1 Web Conference 2Health News:Society of Corporate Compliance and Ethics to host What Compliance Professionals Need to Know about H1N1 Web Conference 3Health News:Select Medical Holdings Corporation Successfully Completes Initial Public Offering of Common Stock 2
    ... Used retrograde to ... establish a Peel-Away ureteral ... The temporary protective Peel-Away ... away as the ureteroscope ...
    The removable inflation/injection adapter allows the cystoscope to be removed after the catheter is in place. Supplied sterile in peel-open packages. Intended for one-time use....
    Radiopaque markers are placed at the proximal and distal ends of the balloon. A special pin vise handle is included to stabilize the wire guide during introduction. Supplied sterile in peel-open pack...
    Used during the performance of balloon dilation procedures to inflate and deflate the balloon and measure the pressure within the balloon during the procedure. Supplied sterile in peel-open packages....
    Medicine Products: